Press

MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory

Aug 2 • 4 min read

VANCOUVER – MindBio Therapeutics Corp. (CSE: MBIO) (Frankfurt: WF6), (the ‘Company’ or ‘MindBio’), a leading biopharmaceutical company in psychiatric medicine development, is pleased to report that it has appointed Haywood Securities Inc. to act as strategic advisor to the Company to support its near-term objectives. Haywood’s services will focus on assisting the Company to secure potential strategic level investment and…

Algernon Pharmaceuticals Announces Closing of Private Placement

Aug 2 • 2 min read

VANCOUVER, British Columbia, Aug. 02, 2024 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces the close of its non-brokered private placement, previously announced on July 11, 2024 and updated on July 31, 2024, for gross proceeds of $408,000 (the “Offering”)…

Tryptamine Therapeutics Limited Appoints David Castle to Its Scientific Advisory Board

Aug 2 • 2 min read

Tryptamine Therapeutics Limited announce the appointment of Professor David Castle to its Scientific Advisory Board (`SAB’). Professor Castle is a leading psychiatric scholar who was recently appointed by the Tasmanian Government as Professor of Psychiatry at the University of Tasmania’s Centre for Mental Health Service Innovation, which was launched in partnership with the Tasmanian Department…

Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC

Aug 1 • 3 min read

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has entered into a $25 million common stock purchase agreement (the “Purchase Agreement”) with White Lion Capital, LLC, (“White Lion”) a California-based institutional investor focused on high-growth, early-stage public companies. Psyence Biomed…

Revitalist Lifestyle and Wellness CEO Kathryn A. Walker to Speak at The AANA Annual Congress on Psychedelics in Anesthesia

Jul 31 • 3 min read

Vancouver, British Columbia–(Newsfile Corp. – July 31, 2024) – Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) (the “Company”) announces that Kathryn A. Walker, CEO of Revitalist Lifestyle and Wellness Ltd., will be presenting at the American Association of Nurse Anesthesiologists (AANA) Annual Congress. The event will take place from August 2-6,…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441